Follow
Translational Oncology
Translational Oncology involves moving scientific discoveries made in a laboratory setting into clinical applications that enhance treatment efficacy and outcomes for cancer patients. Translational Oncology approaches include pre-clinical research, which can be done in an in vivo, in vitro, or ex vivo setting, before validating the laboratory findings with a clinical trial.
-
OCT 17, 2013 | 1:00 PMC.E. CREDITS
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...Speaker: Milan Radovich, PhDOCT 16, 2013 | 1:00 PMC.E. CREDITS
While androgen deprivation therapy (ADT) remains the primary treatment modality for patients with metastatic prostate cancer (PCa), treatment is uniformly marked by progression to castration-...Speaker: Elahe A Mostaghel, MD, PhDOCT 16, 2013 | 12:00 PM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...Speaker: William M. Gallagher, PhD.OCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...Speaker: Michael J Mann, MDOCT 16, 2013 | 7:00 AMC.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...Speaker: Andrew Armstrong, MD ScM FACPOCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...Speaker: Nicola Normanno, MDAUG 22, 2013 | 5:00 PM
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
AUG 21, 2013 | 2:00 PM
Increasingly genome sequence knowledge is unraveling the complexity of rare Mendelian disorders offering hope for our children's medical care through better disease diagnosis and ultimately p...
AUG 21, 2013 | 10:00 AM
C.E. CREDITS
Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retros...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
OCT 17, 2013 | 1:00 PM
C.E. CREDITS
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Speaker:
Milan Radovich, PhD
OCT 16, 2013 | 1:00 PM
C.E. CREDITS
While androgen deprivation therapy (ADT) remains the primary treatment modality for patients with metastatic prostate cancer (PCa), treatment is uniformly marked by progression to castration-...
Speaker:
Elahe A Mostaghel, MD, PhD
OCT 16, 2013 | 12:00 PM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
Speaker:
William M. Gallagher, PhD.
OCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...
Speaker:
Michael J Mann, MD
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
Speaker:
Andrew Armstrong, MD ScM FACP
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
Speaker:
Nicola Normanno, MD
AUG 22, 2013 | 5:00 PM
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
AUG 21, 2013 | 2:00 PM
Increasingly genome sequence knowledge is unraveling the complexity of rare Mendelian disorders offering hope for our children's medical care through better disease diagnosis and ultimately p...
AUG 21, 2013 | 10:00 AM
C.E. CREDITS
Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retros...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...